William Blair Predicts Lower Earnings for Sera Prognostics

Sera Prognostics, Inc. (NASDAQ:SERA) – Investment analysts at William Blair decreased their Q3 2025 earnings estimates for shares of Sera Prognostics in a research note issued to investors on Monday, February 3rd. William Blair analyst A. Brackmann now anticipates that the company will post earnings per share of ($0.24) for the quarter, down from their previous forecast of ($0.23). The consensus estimate for Sera Prognostics’ current full-year earnings is ($0.96) per share. William Blair also issued estimates for Sera Prognostics’ Q4 2025 earnings at ($0.24) EPS and FY2025 earnings at ($0.98) EPS.

Sera Prognostics Trading Up 1.6 %

Shares of SERA stock opened at $5.04 on Wednesday. The firm’s 50 day moving average is $7.27 and its 200 day moving average is $7.30. The stock has a market capitalization of $170.20 million, a P/E ratio of -5.09 and a beta of 0.81. Sera Prognostics has a 12 month low of $4.61 and a 12 month high of $12.35.

Sera Prognostics (NASDAQ:SERA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter in the previous year, the business posted ($0.23) earnings per share.

Hedge Funds Weigh In On Sera Prognostics

A number of institutional investors have recently made changes to their positions in the stock. Barclays PLC grew its position in Sera Prognostics by 321.6% in the third quarter. Barclays PLC now owns 39,450 shares of the company’s stock worth $308,000 after acquiring an additional 30,093 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Sera Prognostics by 7,357.8% during the third quarter. JPMorgan Chase & Co. now owns 884,867 shares of the company’s stock worth $6,902,000 after purchasing an additional 873,002 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Sera Prognostics by 8.9% in the 3rd quarter. Geode Capital Management LLC now owns 586,837 shares of the company’s stock worth $4,578,000 after purchasing an additional 47,969 shares in the last quarter. Quest Partners LLC boosted its holdings in shares of Sera Prognostics by 533.5% in the 3rd quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after purchasing an additional 5,415 shares in the last quarter. Finally, Sanders Morris Harris LLC increased its position in shares of Sera Prognostics by 165.7% during the 4th quarter. Sanders Morris Harris LLC now owns 90,600 shares of the company’s stock valued at $725,000 after purchasing an additional 56,500 shares during the last quarter. Institutional investors own 54.64% of the company’s stock.

Insider Transactions at Sera Prognostics

In related news, insider Robert Gardner Harrison sold 14,209 shares of the stock in a transaction on Friday, January 10th. The stock was sold at an average price of $7.39, for a total value of $105,004.51. Following the sale, the insider now owns 116,837 shares in the company, valued at approximately $863,425.43. This trade represents a 10.84 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Joshua Phillips sold 12,163 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $6.39, for a total value of $77,721.57. Following the transaction, the director now owns 2 shares of the company’s stock, valued at approximately $12.78. The trade was a 99.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 93,215 shares of company stock valued at $666,835 over the last three months. Company insiders own 15.80% of the company’s stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.